Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

563 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.
Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, Terwisscha van Scheltinga AGT, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WPTM, Van der Wall E, van Diest PJ, de Vries EGE, Ntziachristos V, van Dam GM. Lamberts LE, et al. Among authors: de vries j, de vries ege, de jong js, de boer e. Clin Cancer Res. 2017 Jun 1;23(11):2730-2741. doi: 10.1158/1078-0432.CCR-16-0437. Epub 2016 Nov 9. Clin Cancer Res. 2017. PMID: 28119364 Clinical Trial.
Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes.
Schröder CP, Ruiters MHJ, de Jong S, Tiebosch ATMG, Wesseling J, Veenstra R, de Vries J, Hoekstra HJ, de Leij LFMH, de Vries EGE. Schröder CP, et al. Among authors: de vries j, de leij lfmh, de vries ege, de jong s. Int J Cancer. 2003 Sep 10;106(4):611-618. doi: 10.1002/ijc.11295. Int J Cancer. 2003. PMID: 12845661
Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement.
Faneyte IF, Peterse JL, Van Tinteren H, Pronk C, Bontenbal M, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Ten Vergert EM, de Vries EG, Rodenhuis S, van de Vijver MJ. Faneyte IF, et al. Clin Cancer Res. 2004 Jul 1;10(13):4457-63. doi: 10.1158/1078-0432.CCR-03-0054. Clin Cancer Res. 2004. PMID: 15240537 Clinical Trial.
Preclinical characterisation of 111In-DTPA-trastuzumab.
Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de Jong S, Jager PL, de Vries EG. Lub-de Hooge MN, et al. Br J Pharmacol. 2004 Sep;143(1):99-106. doi: 10.1038/sj.bjp.0705915. Epub 2004 Aug 2. Br J Pharmacol. 2004. PMID: 15289297 Free PMC article.
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study.
Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Mulder NH, van der Graaf WT, TenVergert EM, van Tinteren H, de Vries EG. Nieboer P, et al. J Clin Oncol. 2005 Nov 20;23(33):8296-304. doi: 10.1200/JCO.2005.10.167. Epub 2005 Oct 11. J Clin Oncol. 2005. PMID: 16219926 Clinical Trial.
563 results